Within this so-called iPS cell stock project”, iPS cells are derived from the peripheral blood of a healthy person whose homozygous type is the second most common HLA type in Japan”
Nikkei Biotech news release, February 2, 2017
CiRA will offer peripheral blood-derived iPS cells from April 2017